Floatz logo

Anti-Cd19 Anti-Cd20 Bispecific Car-T

B-Cell Lymphoma Stage I

Henan Cancer HospitalCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

317 Active assets in the B-Cell Lymphoma Stage I cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Anti-Cd19 Anti-Cd20 Bispecific Car-T is also rated in:

B-cell acute lymphoblastic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
RefractoryDormant
CC
Indicative ·
41 / 100
View asset →
leukemiaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →